Wanrudee Isaranuwatchai


Affiliate Scientist


Dr. Wanrudee Isaranuwatchai is an Affiliated Scientist at St. Michael’s Hospital, and an Associate Professor at the Institute of Health Policy, Management and Evaluation, University of Toronto, in Canada. She is also a Program Leader and Senior Researcher of the Health Intervention and Technology Assessment Program (HITAP), Thailand.

Her research focuses on how to apply health economics and health technology assessment (HTA) in the real-world setting as well as how to advance methods in economic evaluation (EE). She has experience conducting EEs using various methods with specific interest in the potential of big data in health economics and HTA to support evidence generation and policy-making process.

She has also collaborated with researchers, health professionals, and policy-makers in various areas to help communicate the value of health initiatives using EE. She has contributed to the training on HTA to support health systems in Asia, Africa, and North America. Dr. Isaranuwatchai is dedicated to the creation and use of evidence in healthcare decision making.

Recent Publications

  1. Isaranuwatchai, W, Nakamura, R, Wee, HL, Sarajan, MH, Wang, Y, Soboon, B et al.. What are the impacts of increasing cost-effectiveness Threshold? a protocol on an empirical study based on economic evaluations conducted in Thailand. PLoS One. 2022;17 (10):e0274944. doi: 10.1371/journal.pone.0274944. PubMed PMID:36191016 .
  2. Rattanavipapong, W, Worakijthamrongchai, T, Soboon, B, Luankongsomchit, V, Kongmuangpuk, M, Isaranuwatchai, W et al.. Economic evaluation of endovascular treatment for acute ischaemic stroke in Thailand. BMJ Open. 2022;12 (9):e064403. doi: 10.1136/bmjopen-2022-064403. PubMed PMID:36167373 PubMed Central PMC9516067.
  3. Moran, AE, Farrell, M, Cazabon, D, Sahoo, SK, Mugrditchian, D, Pidugu, A et al.. Building the health-economic case for scaling up the WHO-HEARTS hypertension control package in low- and middle-income countries. Rev Panam Salud Publica. 2022;46 :e140. doi: 10.26633/RPSP.2022.140. PubMed PMID:36071923 PubMed Central PMC9440739.
  4. Pheerapanyawaranun, C, Wang, Y, Kittibovorndit, N, Pimsarn, N, Sirison, K, Teerawattananon, Y et al.. COVID-19 Vaccine Hesitancy Among Health Care Workers in Thailand: The Comparative Results of Two Cross-Sectional Online Surveys Before and After Vaccine Availability. Front Public Health. 2022;10 :834545. doi: 10.3389/fpubh.2022.834545. PubMed PMID:35979452 PubMed Central PMC9376379.
  5. Wang, Y, Luangasanatip, N, Pan-Ngum, W, Isaranuwatchai, W, Prawjaeng, J, Saralamba, S et al.. Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic. Eur J Health Econ. 2022; :. doi: 10.1007/s10198-022-01505-2. PubMed PMID:35951243 PubMed Central PMC9366779.
  6. Teerawattananon, Y, Dabak, SV, Isaranuwatchai, W, Lertwilairatanapong, T, Shafie, AA, Suwantika, AA et al.. What Can We Learn From Others to Develop a Regional Centre for Infectious Diseases in ASEAN? Comment on "Operationalising Regional Cooperation for Infectious Disease Control: A Scoping Review of Regional Disease Control Bodies and Networks". Int J Health Policy Manag. 2022; :. doi: 10.34172/ijhpm.2022.7281. PubMed PMID:35942957 .
  7. Rodrigues, IB, Wagler, JB, Keller, H, Thabane, L, Weston, ZJ, Straus, SE et al.. Encouraging older adults with pre-frailty and frailty to "MoveStrong": an analysis of secondary outcomes for a pilot randomized controlled trial. Health Promot Chronic Dis Prev Can. 2022;42 (6):238-251. doi: 10.24095/hpcdp.42.6.02. PubMed PMID:35766913 PubMed Central PMC9388057.
  8. Arciero, V, Luo, J, Parmar, A, Dai, WF, Beca, JM, Raphael, MJ et al.. Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer. JNCI Cancer Spectr. 2022;6 (4):. doi: 10.1093/jncics/pkac047. PubMed PMID:35758620 PubMed Central PMC9346632.
  9. McMain, SF, Chapman, AL, Kuo, JR, Dixon-Gordon, KL, Guimond, TH, Labrish, C et al.. The Effectiveness of 6 versus 12 Months of Dialectical Behavior Therapy for Borderline Personality Disorder: A Noninferiority Randomized Clinical Trial. Psychother Psychosom. 2022; :1-16. doi: 10.1159/000525102. PubMed PMID:35738244 .
  10. Loong, D, Pham, B, Amiri, M, Saunders, H, Mishra, S, Radhakrishnan, A et al.. Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults. Value Health. 2022;25 (8):1439-1458. doi: 10.1016/j.jval.2022.03.011. PubMed PMID:35659487 .
Search PubMed

Affiliations & Other Activities

  • Scientist, Li Ka Shing Institute
  • Assistant Professor, Institute for Health Policy, Management and Evaluation, University of Toronto